5-HTTLPR polymorphism, mood disorders and MDMA use in a 3-year follow-up study

Addiction Biology

Volumn 15, Issue 1, 2010, Pages 15-22

  Martín Santos, Rocío ^a,b   Torrens, Marta ^a,c   Poudevida, Sandra ^a   Langohr, Klaus ^a,d   Cuyás, Elisabet ^a,c   Pacifici, Roberta ^e   Farré, Magí ^a,c   Pichini, Simona ^e   De La Torre, Rafael ^a,f  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^f UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Cannabis; Ecstasy; Incidence rate; MDMA; Non substance use disorders; Substance use disorders

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABIS; COCAINE;

ADULT; ARTICLE; CANNABIS ADDICTION; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DEPENDENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; PRIORITY JOURNAL; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; ALLELES; AMPHETAMINE-RELATED DISORDERS; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MARIJUANA ABUSE; MOOD DISORDERS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; YOUNG ADULT;

EID: 71949112153     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2009.00180.x     Document Type: Article

References (34)

1. Aragon T (2009) Epitools: epidemiology tools. R package version 0.5-3. Available at: http://CRAN.R-project.org/packages=epitools. Accessed 18 September 2009.
2. Belmaker RH, Agam G (2008) Major depressive disorder. N Engl J Med 358 : 55 68.
3. Bolanos CA, Barrot M, Berton O, Wallace-Black D, Nestler EJ (2003) Methilphenidate treatment during pre-and periadolescence alters behavioural responses to emotional stimuli at adulthood. Biol Psychiatry 54 : 1317 1329.
4. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harringthon H (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301 : 386 389.
5. Daumann J, Hensen G, Thimm B, Rezk M, Till B, Gouzoulis-Mayfrank E (2004) Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacology (Berl) 173 : 398 404.
6. De la Torre R, Farré M (2004) Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 25 : 505 508.
7. Durdle H, Lundahl LH, Johanson CE, Tancer M (2008) Major depression: the relative contribution of gender, MDMA, and cannabis use. Depress Anxiety 25 : 241 247.
8. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2008) Annual report on the state of the drugs problem in Europe. Available at: http://www.emcdda.europa.eu./ Accessed 4 June 2009.
9. Furlong RA, Ho L, Walsh C, Rubinsztein JS, Jain S, Paykel ES, Easton DF, Rubinsztein DC (1998) Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders. Am J Med Genet 81 : 58 63.
10. Gonda X, Juhasz G, Laszik A, Rihmer Z, Bagdy G (2005) Subthreshold depression is linked to the functional polymorphism of the 5HT transporter gene. J Affect Disord. 87 : 291 297.
11. Gonzalez JR, Armengol L, Guinó E, Solé X, Moreno V (2009) SNPassoc: SNPs-based whole genome association studies. R package version 1.6-0. Available at: http://CRAN.R-project.org/package=SNPassoc. Accessed 18 September 2009.
12. Gouzoulis-Mayfrank E, Daumann J (2006) Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction 101 : 348 361.
13. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy Pharmacol Rev 55 : 463 508.
14. Hasin DS, Samet S, Nunes E, Meydan J, Matseoane K, Waxman R (2006) Diagnosis of comorbid disorders in substance users: Psychiatric Research Interview for Substance and Mental Disorders (PRISM-IV). Am J Psychiatry 163 : 689 696.
15. Hernández-López C, Farré M, Roset PN, Menoyo E, Pizarro N, Ortuño J, Torrens M, Camí J, de La Torre R (2002) 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther 300 : 236 244.
16. Huizink AC, Fernidand RF, van der Ende J, Verhulst FC (2006) Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study. BMJ 232 : 825 828.
17. Kendler KS, Kuhn JW, Vittum J, Prescott CA, Riley B (2005) The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch Gen Psychiatry 62 : 529 535.
18. Keyes KM, Martins SS, Hasin DS (2008) Past 12-month and lifetime comorbidity and poly-drug use of ecstasy users among young adults in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 97 : 139 149.
19. Kish SJ, Furukawa Y, Ang L, Vorce SP, Kalasinsky KS (2000) Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user. Neurology 55 : 294 296.
20. Lieb R, Schuetz CG, Pfister H, von Sydow K, Wittchen HU (2002) Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 68 : 195 207.
21. O'Mathúna B, Farré M, Rostami-Hodjegan A, Yang J, Cuyàs E, Torrens M, Pardo R, Abanades S, Maluf S, Tucker GT, de la Torre R (2008) The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol 28 : 523 529.
22. Pacifici R, Zuccaro P, Farré M, Poudevida S, Abanades S, Pichini S, Langohr K, Segura J, Torre R (2007) Combined immunomodulating properties of 3,4-methylenedioxymethamphetamine (MDMA) and cannabis in humans. Addiction 102 : 931 936.
23. Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB, den Heeten GJ, van den Brink W (2001) Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358 : 1864 1869.
24. Roiser JP, Cook LJ, Cooper JD, Rubinsztein DC, Sahakian BJ (2005) Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users. Am J Psychiatry 162 : 609 612.
25. Rothman K, Greenland S, Lash T (2008) Modern Epidemiology, 3rd edn. Philadelphia, PA : Lippincott Williams & Wilkins.
26. Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R (1998) MDMA (ecstasy) consumption in the context of poly-drug abuse: a report on 150 patients. Drug Alcohol Depend 52 : 85 90.
27. Schuckit MA, Smith TL, Danko GP, Pierson J, Trim R, Nurnberger JI, Kramer J, Kuperman S, Bierut LJ, Hesselbrock V (2007) A comparison of factors associated with substance-induced versus independent depressions. J Stud Alcohol Drugs 68 : 805 812.
28. Sumnall HR, Cole JC (2005) Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: a meta-analysis. J Psychopharmacol 19 : 84 92.
29. Thomasius R, Petersen KU, Zapletalova P, Wartberg L, Zeichner D, Schmoldt A (2005) Mental disorders in current and former heavy ecstasy (MDMA) users. Addiction 100 : 1310 1319.
30. Topp L, Barker B, Degenhardt L (2004) The external validity of results derived from ecstasy users recruited using purposive sampling strategies. Drug Alcohol Depend 73 : 33 40.
31. Torrens M, Martin-Santos R, Samet S (2006) Importance of clinical diagnoses for comorbidity studies in substance use disorders. Neurotox Res 10 : 253 261.
32. Torrens M, Serrano D, Astals M, Pérez-Domínguez G, Martín-Santos R (2004) Diagnosing psychiatric comorbidity in substance abusers. Validity of the Spanish versions of Psychiatric Research Interview for Substance and Mental Disorders (PRISM) and the Structured Clinical Interview for DSM-IV (SCID-IV). Am J Psychiatry 161 : 1231 1237.
33. Vittinghoff E, McCulloch CE (2007) Relaxing the rule of ten events per variable in logistic and cox regression. Am J Epidemiol 165 : 710 718.
34. Wilhelm K, Mitcheli PB, Niven H, Finch A, Wedgwood L, Scimone A, Blair IP, Parker G, Shofield PR 2006) Life events, first depression onset and the serotonin transporter gene. Br J Psychiatry 188 : 210 205.